Efforts to extend human lifespan now span a wide spectrum, from well-established lifestyle interventions such as improved diet and regular exercise to controversial approaches including the infusion of blood plasma from young donors. While the former is backed by decades of scientific research, the latter has already drawn two warnings from the U.S. Food and Drug Administration (FDA), which has stressed that such treatments lack any demonstrated clinical benefit.
In effect, the pursuit of longevity has come to include both straightforward behavioral changes and what critics describe as costly pseudoscience.
Yet, as Axios reported, researchers point to a compelling middle ground grounded in biology: the idea that aging itself is a modifiable biological process that could, in principle, be treated like many other conditions in the human body.
According to Felipe Sierra, the field is divided into two broad currents. On one side, he reportedly said, there is serious scientific work showing considerable promise, though much of it has yet to be properly tested in humans for practical and regulatory reasons. On the other, he warned, there are “purveyors of miracle cures” making claims that go far beyond what current evidence can support.
A recent development illustrating both the promise and uncertainty of the field involves an experimental gene therapy trial targeting eye disease. The first patient has reportedly received a treatment aimed at conditions such as glaucoma, which can lead to blindness.
The therapy targets three genes believed to enable partial “reprogramming” of aged cells. In this case, researchers are attempting to restore the function of neurons that connect the eye to the brain, potentially reversing damage associated with degeneration.
The company behind the trial, Life Biosciences, was co-founded by Harvard professor David Sinclair, one of the most prominent—and also most debated—figures in longevity science. The firm describes its mission as developing cellular rejuvenation therapies intended to “reverse age-related diseases.”
However, researchers emphasize that the current phase of the study is focused solely on safety. Even if results are positive, they note, significant work remains before any conclusions can be drawn about effectiveness.
Future trials, they add, would need to demonstrate whether the therapy can treat glaucoma specifically, rather than broadly influencing biological aging. Still, experts suggest that success at this stage could serve as an important proof of concept for the broader field of cellular reprogramming.
As Matt Kaeberlein observed, if epigenetic reprogramming were to succeed, it could mark a historic turning point for the discipline.
Despite the science still being in its early stages, investment in longevity biotech has surged, with tech billionaires driving what some observers describe as a high-stakes “gold rush.”
Among the leading startups, NewLimit, founded by Coinbase CEO Brian Armstrong, has reportedly reached a $3.1 billion valuation, even though its first human trials are not expected until next year, according to the Wall Street Journal.
Retro Biosciences, backed by OpenAI CEO Sam Altman, has raised $180 million and is valued at about $1.8 billion. Meanwhile, Altos Labs launched in 2022 with roughly $3 billion in funding, including support linked to Amazon founder Jeff Bezos, highlighting the scale of elite investor interest in the field.
